Valneva SE Sponsored ADR (NASDAQ:VALN) Receives Consensus Rating of “Hold” from Analysts

Valneva SE Sponsored ADR (NASDAQ:VALN) has earned an average recommendation of “Hold” from the five research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $11.9750.

VALN has been the topic of several research analyst reports. The Goldman Sachs Group cut shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target on the stock. in a research note on Wednesday. Guggenheim set a $11.00 price target on shares of Valneva in a research note on Thursday, April 16th.

Institutional Trading of Valneva

Several hedge funds have recently modified their holdings of VALN. VSM Wealth Advisory LLC boosted its stake in Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after acquiring an additional 5,000 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Valneva in the fourth quarter valued at approximately $44,000. JPMorgan Chase & Co. bought a new position in Valneva in the third quarter valued at approximately $124,000. XTX Topco Ltd bought a new position in Valneva in the fourth quarter valued at approximately $94,000. Finally, Marex Group plc bought a new position in Valneva in the second quarter valued at approximately $64,000. 11.39% of the stock is owned by institutional investors.

Valneva Price Performance

VALN opened at $5.93 on Wednesday. Valneva has a one year low of $5.43 and a one year high of $12.25. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.38 and a quick ratio of 1.85. The company’s 50 day simple moving average is $8.74 and its 200-day simple moving average is $9.11. The stock has a market capitalization of $510.63 million, a P/E ratio of -3.75 and a beta of 1.97.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.68) EPS for the quarter. Valneva had a negative net margin of 67.64% and a negative return on equity of 76.81%. The company had revenue of $55.92 million for the quarter. Sell-side analysts anticipate that Valneva will post -0.81 earnings per share for the current fiscal year.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.